title: Effects of topical administration of 12-methyl tetradecanoic acid (12-MTA) on the development of corneal angiogenesis.
abstract: Corneal vascularisation is a potentially devastating occurrence that can cause blindness. Currently, treatments for this condition are limited. In these studies, we have investigated a novel inhibitor of angiogenesis, 12-methyl tetradecanoic acid (12-MTA), to treat corneal vascularisation in mouse models of corneal alkali injury and corneal Pseudomonas aeruginosa infection. The effectiveness of 12-MTA was compared to treatment with dexamethasone. 12-MTA was found to be at least as effective as dexamethasone in reducing the angiogenesis that occurs following alkali injury or P. aeruginosa infection of the cornea. The major effect of both 12-MTA and dexamethasone in these models was to reduce the linear incursion of new blood vessels into the central cornea. A significantly better result was obtained at 14 days post-alkali injury when treatment was not delayed. A major advantage of treatment of alkali injury with 12-MTA compared to that with dexamethasone was the finding that there was a 5-fold less level of PMN infiltration and no persistent epithelial defects in corneas treated with 12-MTA compared to 50% of those treated with dexamethasone. Our studies indicate that 12-MTA may provide clinically significant advantages over conventional steroids for the treatment of vessel growth in the cornea.
authors.affiliation: Institute for Eye Research, Level 4, Rupert Myers Building, Gate 14, Barker Street, Kensington, Sydney, NSW 2052, Australia.
authors.forename: Nerida
authors.initials: N
authors.lastname: Cole
authors.forename: Emma B H
authors.initials: EB
authors.lastname: Hume
authors.forename: Isabelle
authors.initials: I
authors.lastname: Jalbert
authors.forename: Ajay Kumar
authors.initials: AK
authors.lastname: Vijay
authors.forename: Ravi
authors.initials: R
authors.lastname: Krishnan
authors.forename: Mark D P
authors.initials: MD
authors.lastname: Willcox
mesh_terms: D000287:Administration, Topical; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000818:Animals; D003315:Cornea / Q000098:blood supply* / Q000382:microbiology; D016510:Corneal Neovascularization / Q000209:etiology / Q000517:prevention & control*; D003907:Dexamethasone / Q000008:administration & dosage; D004195:Disease Models, Animal; D005126:Eye Burns / Q000139:chemically induced / Q000150:complications; D015818:Eye Infections, Bacterial / Q000382:microbiology / Q000473:pathology; D005227:Fatty Acids / Q000008:administration & dosage*; D005938:Glucocorticoids / Q000008:administration & dosage; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D011552:Pseudomonas Infections / Q000382:microbiology / Q000473:pathology; D012972:Sodium Hydroxide
chemical_list: D020533:Angiogenesis Inhibitors; D005227:Fatty Acids; D005938:Glucocorticoids; C069642:aseanostatin P5; D012972:Sodium Hydroxide; D003907:Dexamethasone